BVI announced it has acquired the ophthalmic viscoelastic device (OVD) assets from Austrian-based Croma. In addition to the acquisition of existing products, BVI and Croma have embarked on an R&D collaboration on additional products that will come to market.
Terms of the deal were not disclosed.
With the immediate closing of this transaction, BVI launches NuVisc PRO, a new Cohesive OVD in Europe with additional geographies to follow as regulatory pathways are met. The clinical study for NuVisc PRO was completed in December 2019 at the Vienna Institute for Research in Ocular Surgery (VIROS) and demonstrated the safety and efficacy[i]. NuVisc PRO will provide surgeons through its specific combination of HA concentration and high molecular weight a distinct OVD that can be used throughout each of the stages in cataract surgery.
“We searched across the globe to find the highest quality OVDs to complement and expand our portfolio,” Shervin Korangy, President and CEO of BVI, said in a company news release. “Croma’s track record, innovation, quality and safety in HA production is unparalleled in the industry. This partnership with the Prinz family will position BVI to further innovate in this product category for ophthalmology.”
Croma, founded in 1976, is led by the original founder, Gerhard Prinz and his sons Andreas and Martin Prinz. During the 1980’s, Croma started its journey in ophthalmology including viscoelastics. In the subsequent decades it became a world leader in hyaluronic acid manufacturing producing 40 million units over 2 decades. Following the sale of a number of Croma’s assets more than 5 years ago, the company had taken a pause from ophthalmology until the recent development of what is now NuVisc PRO.
“We are thrilled about our partnership with BVI. We will leverage their expertise in ophthalmology and our expertise in OVD development and production” said Andreas Prinz, CCO and co-owner of Croma. “We quickly recognized the scale of global growth opportunities that BVI could bring. The entrepreneurial mindset at BVI is refreshing and different than what we have seen in the ophthalmic marketplace.”